OC
GEVA

Oppenheimer & Co’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Oppenheimer & Co’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-4,000
Closed -$254K – 1498
2013
Q3 		$254K Buy
+4,000
New +$197K 0.01% 1047

Other funds holding GEVA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Oppenheimer & Co's GEVA Position: Q4 2013 in Review

Oppenheimer & Co sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q4 2013, closing a stake of 4,000 shares — an estimated $254K sold.

Oppenheimer & Co first reported a position in GEVA in Q3 2013 and held it in 1 quarter. The position peaked at $254K in Q3 2013. 84 funds tracked by Wall St. Rank hold GEVA as of Q4 2013.

  • Oppenheimer & Co reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q4 2013 after selling out during the quarter.
  • Oppenheimer & Co sold 4,000 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q4 2013, an estimated $254K.
  • Oppenheimer & Co first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q3 2013 and held it in 1 quarter.
  • Oppenheimer & Co's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $254K in Q3 2013.
  • 84 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q4 2013.

Based on Oppenheimer & Co's 13F filing for Q4 2013, filed 12 Feb 2014.